Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M

Memorial Sloan Kettering Cancer Center

Other

72

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

102

Indications↗

Distinct diseases across all programs

1,526

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

72 drugs in development

Approved4

Phase 38

Phase 233

Phase 127

Preclinical18

By Therapeutic Area

top 6

Oncology

6469%

Metabolic & Endocrine

33%

Gastroenterology

22%

Immunology

22%

Nephrology

22%

Psychiatry

11%

R&D Momentum

100/100

Pipeline Velocity

79/100

Trial Completion Rate

91/100

Pipeline Concentration

50/100

Pipeline Freshness

38/100

Strategic Signals

↗Active in Gastroenterology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

Active, not recruiting

Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study

Active, not recruiting

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

Active, not recruiting

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Clinical Trial Optimizing Tumor Ablation for Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures

Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined With Ruxolitinibfor Patients With Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)

Phase I Study of Valemetostat and Atezolizumab as Maintenance Therapy for Patients With Extensive-Stage Small Cell Lung Cancer

ALTITUDE - ALTernating Induction Therapies to Achieve Undetectable Disease Endpoints: A Phase 1/2 Alternating Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-risk Newly Diagnosed Multiple Myeloma

Active, not recruiting

Pembrolizumab in Combination With Gemcitabine for Previously Treated Mycosis Fungoides and Sézary Syndrome: Efficacy and Characterization of Immune Response

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

—

—

—

1

Cardiovascular(1 drug)

Gastroenterology(2 drugs)

1

1

—

—

1

Gastroenterology(2 drugs)

Hematology(1 drug)

—

—

1

—

—

Hematology(1 drug)

Immunology(2 drugs)

1

1

—

—

1

Immunology(2 drugs)

Infectious Disease(1 drug)

—

—

—

—

1

Infectious Disease(1 drug)

Metabolic & Endocrine(3 drugs)

1

—

—

—

3

Metabolic & Endocrine(3 drugs)

Nephrology(2 drugs)

1

—

—

—

1

Nephrology(2 drugs)

Neurology(1 drug)

—

—

—

—

1

Neurology(1 drug)

Oncology(64 drugs)

11

23

28

7

3

Oncology(64 drugs)

Psychiatry(1 drug)

—

—

—

—

1

Psychiatry(1 drug)

Rare Disease(1 drug)

1

—

—

—

—

Rare Disease(1 drug)

Unknown / Other(14 drugs)

4

3

4

1

3

Unknown / Other(14 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)